Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Share-based Compensation (2021 - 2025)

Verrica Pharmaceuticals (VRCA) has 5 years of Share-based Compensation data on record, last reported at $686000.0 in Q4 2025.

  • For Q4 2025, Share-based Compensation fell 9.26% year-over-year to $686000.0; the TTM value through Dec 2025 reached $3.3 million, down 53.69%, while the annual FY2025 figure was $3.3 million, 53.69% down from the prior year.
  • Share-based Compensation reached $686000.0 in Q4 2025 per VRCA's latest filing, down from $718000.0 in the prior quarter.
  • Across five years, Share-based Compensation topped out at $9.7 million in Q3 2023 and bottomed at $686000.0 in Q4 2025.
  • Average Share-based Compensation over 5 years is $1.8 million, with a median of $1.4 million recorded in 2021.
  • Peak YoY movement for Share-based Compensation: skyrocketed 583.86% in 2023, then crashed 78.18% in 2024.
  • A 5-year view of Share-based Compensation shows it stood at $1.3 million in 2021, then fell by 11.36% to $1.2 million in 2022, then soared by 77.2% to $2.1 million in 2023, then tumbled by 63.57% to $756000.0 in 2024, then dropped by 9.26% to $686000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Share-based Compensation were $686000.0 in Q4 2025, $718000.0 in Q3 2025, and $888000.0 in Q2 2025.